UnknownNot Applicable

Management of Oxaliplatin-related Gastroesophageal Variceal Bleeding

China100 participantsStarted 2021-11-03

Plain-language summary

In this randomized controlled study, we aim to compare the efficacy and safety of these two interventions in patients with oxaliplatin-induced gastroesophageal variceal bleeding.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Having received oxaliplatin-based chemotherapy for at least one cycle
✓. History of variceal bleeding (including hematemesis or melena)
✓. Portal hypertension confirmed by CT or MRI
✓. Esophageal and / or gastric varices confirmed by endoscopy
✓. Informed consent signed

Exclusion criteria

✕. With serious life-threatening diseases of circulation / blood / respiratory system
✕. With known causes of liver cirrhosis (hepatitis B, hepatitis C, autoimmune, schistosomiasis, non-alcoholic fatty liver disease, and etc.)
✕. With contraindications of endoscopic treatments and TIPS;
✕. Participation refused

What they're measuring

24-week re-bleeding

Timeframe: 24 weeks

Trial details

NCT IDNCT05141617

SponsorShanghai Zhongshan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

Contact for this trial

Xiaoquan HUANG, M.D.

008618801733835 huang.xiaoquan@zs-hospital.sh.cn

View on ClinicalTrials.gov More Gastroesophageal Varices Hemorrhage trials